← All trials
NCT06076304
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Oct 10, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 144
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Georgetown UniversityLead sponsor
- Georgetown UniversityOverall official - principal investigator
- Georgetown UniversitySponsor investigator
- Georgetown UniversityCollaborator
- Patient-Centered Outcomes Research InstituteCollaborator
- Pennsylvania State UniversityCollaborator
- University of WashingtonCollaborator
- University of WisconsinCollaborator
- Virginia Commonwealth UniversityCollaborator
- Georgetown UniversityOfficial
- University of California, Los AngelesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.